PMID- 20082996
OWN - NLM
STAT- MEDLINE
DCOM- 20100331
LR  - 20131121
IS  - 1873-5126 (Electronic)
IS  - 1353-8020 (Linking)
VI  - 15 Suppl 3
DP  - 2009 Dec
TI  - [Advances in the medical treatment of Parkinson's disease].
PG  - S22-5
LID - 10.1016/S1353-8020(09)70773-4 [doi]
AB  - Parkinson's disease (PD) is a common progressive neurodegenerative disorder. 
      Dopamine replacement therapy considerably reduces motor handicap. Although 
      levodopa continues as the gold standard for efficacy, its chronic use is 
      associated with potentially disabling motor complications. Strategies to treat 
      levodopa-related motor complications are only partially effective. Best results 
      are currently achieved with invasive strategies via subcutaneous (s.c.) or 
      intraduodenal delivery of apomorphine or levodopa, or deep brain stimulation of 
      the subthalamic nucleus. This presentation will develop the current treatment 
      principles for PD: (1) L-dopa does not accelerate disease progression, (2) no 
      treatment modality exerts neuroprotective effects, (3) L-dopa is more effective 
      than dopamine agonists in alleviating motor symptoms and improving the activities 
      of daily living (ADL) score, in parkinsonian patients, (4) Treatment with 
      dopamine agonist is associated with fewer motor complications than L-dopa. (5) 
      Dopamine agonist therapy is associated with more frequent adverse events than 
      L-dopa therapy, such as hallucinations and somnolence. There is no evidence of a 
      long-term benefit with initial dopamine agonist therapy.
FAU - Chana, Pedro
AU  - Chana P
AD  - Neurologia, Centro de trastornos del Movimiento, Facultad de Ciencias Medicas, 
      Universidad de Santiago de Chile, Chile. chanapedro@gmail.com
LA  - spa
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Avances en tratamiento medico de la enfermedad de Parkinson.
PL  - England
TA  - Parkinsonism Relat Disord
JT  - Parkinsonism & related disorders
JID - 9513583
RN  - 0 (Antiparasitic Agents)
RN  - 0 (Dopamine Agonists)
RN  - 0 (Monoamine Oxidase Inhibitors)
RN  - 46627O600J (Levodopa)
SB  - IM
MH  - Antiparasitic Agents/adverse effects/*therapeutic use
MH  - Disorders of Excessive Somnolence/chemically induced
MH  - Dopamine Agonists/adverse effects/therapeutic use
MH  - Hallucinations/chemically induced
MH  - Humans
MH  - Levodopa/adverse effects/therapeutic use
MH  - Monoamine Oxidase Inhibitors/therapeutic use
MH  - Parkinson Disease/*drug therapy/psychology
RF  - 25
EDAT- 2010/01/30 06:00
MHDA- 2010/04/01 06:00
CRDT- 2010/01/20 06:00
PHST- 2010/01/20 06:00 [entrez]
PHST- 2010/01/30 06:00 [pubmed]
PHST- 2010/04/01 06:00 [medline]
AID - S1353-8020(09)70773-4 [pii]
AID - 10.1016/S1353-8020(09)70773-4 [doi]
PST - ppublish
SO  - Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S22-5. doi: 
      10.1016/S1353-8020(09)70773-4.